Oxford BioMedica, a gene therapy company, announces that Mike McDonald has been promoted to the board as an executive director with immediate effect and he maintains his title of chief medical officer
Mike McDonald's primary responsibilities include the company's clinical development activities and regulatory affairs.
He has over 20 years of experience in clinical drug development and regulatory leadership.
He joined Oxford BioMedica in September 2005 from Seattle Genetics, a US-based biotechnology company, where he was chief medical officer.
McDonald spent nine years with Eli Lilly serving as worldwide vice president, clinical research and medical affairs, and was previously at SmithKline Beecham for seven years where he was involved in worldwide clinical development, regulatory management and was a member of the pharmaceutical development strategy committee.
From these positions McDonald contributed to the successful registration and commercialisation of many important pharmaceuticals.
He received his medical degree from Edinburgh University, he is a member of the Royal College of Physicians in London, holds a diploma in pharmaceutical medicine and is a fellow of the Faculty of Pharmaceutical Physicians.
Commenting on the board appointment, Professor Alan Kingsman, chief executive of Oxford BioMedica, said: "Mike has already made a significant and valuable contribution to the company since joining last year and has been instrumental in the preparations for our planned Phase III trial of TroVax in renal cell carcinoma.
"We are delighted to welcome him to the board."
